Total: $2,301.257M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
| | ||||
Adherex Technologies Inc. (Canada; TSE:AHX) |
Private placement of convertible notes |
N/A |
C$3 |
Adherex raised about US$2.2M in the private placement (6/24) |
|
||||
AMDL Inc. |
Private placement of units |
2.6S |
$0.887 |
AMDL raised about $887,000 net in a private offering of units consisting of convertible notes and stock purchase warrants; the notes were converted into 2.6M shares (6/23) |
|
||||
Amylin Pharmaceuticals |
Private placement of convertible senior notes |
N/A |
$150 |
Amylin raised $150M in a private placement of 2.25% convertible senior notes due 2008 (6/18) |
|
||||
Axonyx Inc. |
Private placement of common stock and exercise of warrants |
0.23S, 0.9S and W for 0.46S |
$2.9 |
Axonyx raised $2.9M through the exercise of outstanding warrants and the placement of common shares and warrants (6/13) |
|
|
|||
BioMarin Pharmaceutical |
Private placement of convertible subordinated notes |
N/A |
$125 |
BioMarin raised $125M in a private placement of convertible subordinated notes due 2008 (6/17) |
|
||||
Bioniche Life |
Private placement of common stock and warrants |
1.2S and W for 0.3S |
C$2.2 (US$1.6) |
Bioniche raised US$1.6M with the placement of 1.2M shares; investors also received 306,250 three-year warrants to purchase common shares (6/9) |
|
||||
Biota Holdings Ltd. (Australia; ASX:BTA) |
Private placement of common stock |
5.6S |
A$2.5 (US$1.6) |
Biota Holdings raised US$1.6M with the placement of 5.6M shares to a subsidiary of Babcock & Brown Pty. Ltd. (6/10) |
|
||||
Cell Therapeutics |
Private placement of convertible senior subordinated notes |
N/A |
$75 |
Cell Therapeutics raised $75M in the sale of 4% convertible senior subordinated notes due 2010 (6/18) |
|
||||
Cephalon Inc. |
Private placement of convertible subordinated notes |
N/A |
$750 |
Cephalon priced $600M worth of convertible subordinated notes, which will be issued in two tranches (6/6); the purchaser exercised an option to purchase an additional $150M in notes (6/13) |
|
||||
Cobra BioManufacturing plc (UK; LSE:CBF) |
Private placement of common stock |
6.5S |
£4.65 (US$7.4) |
Cobra raised US$7.4M through the sale of 6.5M shares (6/4**) |
|
|
|||
ConjuChem Inc. (Canada; TSE:CJC) |
Private placement of common stock |
7.5S |
C$12 (US$8.9) |
ConjuChem raised US$8.9M after entering an agreement to privately place 7.5M shares with a syndicate of underwriters led by Yorkton Securities Inc. (6/13) |
|
||||
Corixa Corp. |
Private placements of common stock and convertible subordinated notes |
3.7S |
$130 |
Corixa raised about $30 million through the issuance of shares to The Sprout Group, and another $85M through the placement of notes with unspecified instutional buyers (6/10); it raised another $15M through the exercise of the overallotment option (6/23) |
|
||||
CV Therapeutics |
Private placement of senior subordinated convertible debentures |
N/A |
$100 |
CV raised $100M through the sale of senior subordinated convertible debentures (6/13) |
|
||||
Cytogen Corp. |
Private placement of common stock and warrants |
1S and W for 0.3S |
$5 |
Cytogen raised $5M with the placement of 1M shares; investors also will receive warrants to purchase 315,790 shares (6/9) |
|
||||
Dendreon Corp. (DNDN) |
Private placement of common stock |
4.4S |
$30.7 |
Dendreon raised $30.7M through the sale of 4.4M shares to Baystar Capital, Mazama Capital Management and an existing shareholder (6/13) |
|
||||
Discovery Laboratories Inc. (DSCO) |
Private placement of common stock and warrants |
5S and W for 1S |
$27.5 |
Discovery Laboratories raised $27.5M through the private placement, which included Quaker BioVentures Inc., BayStar Capital Management LLC, Special Situations Funds, PharmaBio Development Inc., Laboratorios Del Dr. Esteve and other selected investors; Gerard Klauer Mattison & Co. acted as the placement agent (6/20) |
|
||||
Durect Corp. |
Private placement of convertible notes |
N/A |
$50 |
Durect raised $50M through the placement of convertible notes (6/13) |
|
||||
Generex |
Private placement of common stock and warrants |
0.667S |
$1 |
Generex raised $1M through the placement of 666,667 common shares to an existing accredited institutional investor (6/10) |
|
||||
Guilford Pharmaceuticals |
Private placement of convertible sub-ordinated notes |
N/A |
$60 |
Guilford agreed to sell $60M of convertible subordinated notes, which are convertible into stock at $6.24 per share (6/13) |
|
||||
Hollis-Eden Pharmaceuticals Inc. (HEPH) |
Private placement of common stock |
1.3S |
$15 |
Hollis-Eden raised about $15M through the private placement (6/20) |
|
||||
ICOS |
Private placement of convertible subordinated notes |
N/A |
$250 |
ICOS raised $250M with a private placement of 2% convertible subordinated notes due 2023 (6/17) |
|
||||
Inex Pharmaceuticals Corp. (Canada; TSE:IEX) |
Private placement of common stock |
4.6S |
C$25.07 (US$18.58) |
Inex raised US$18.58M in the financing with investors BMO Nesbitt Burns, Raymond James, Desjardins Securities and Orion Securities; the investors also have an overallotment option on 690,000 shares in the bought-deal financing (6/27) |
|
||||
Integrated BioPharma Inc. (AMEX:INB) |
Private placement of convertible preferred stock |
0.0095S |
$9.5 |
Integrated raised $9.5M from the sale of 9,500 newly issued shares of Series A convertible preferred stock priced at $1,000 apiece (6/30) |
|
||||
Introgen Therapeutics Inc. (INGN) |
Private placement of common stock |
2S |
$11.5 |
Introgen raised $11.5M through the private placement of 2M common shares (6/18) |
|
||||
Labopharm Inc. (Canada; TSE:DDS) |
Private placement of common stock |
N/A |
C$22 (US$16.3) |
Labopharm raised about US$16.3M in a bought-deal financing led by National Bank Financial, which also has a 15% overallotment option (6/27) |
|
||||
Medicure Inc. |
Private placement of common stock |
8.2S |
C$7 (US$5.65) |
Medicure raised US$5.65M with the sale of 8.2M common shares to Research Capital Corp., First Associates Investments Inc. and Paradigm Capital Inc. (6/13) |
|
||||
MedMira Inc. |
Loan facility |
0.037S and 0.147W |
C$0.625 (US$0.46) |
Company completed arrangements for a US$460,476 loan facility with individual Martin Fiuffre; the company agreed to issue the lender 36,765 common shares and 147,059 warrants (6/9) |
|
||||
Nektar Therapeutics (NKTR) |
Private placement of convertible subordinated notes |
N/A |
$100 |
Nektar raised $100M in a private offering to qualified institutional buyers (6/23) |
|
||||
NPS Pharmaceuticals Inc. (NPSP) |
Private placement of convertible notes |
N/A |
$170 |
NPS raised $170M through the private placement of convertible notes (6/13) |
|
||||
Oncolytics Biotech Inc. TSE:ONC) |
Private placement of common stock |
6.9S |
C$2.6 (US$1.9) |
Oncolytics raised US$1.9M through the sale of 6.9M shares of Transition Therapeutics Inc., which was (Canada; ONCY; all of its interest in the company (6/6) |
|
||||
Oncolytics Biotech Inc. (Canada; ONCY; TSE:ONC) |
Private placement of units |
2U |
C$6 (US$4.4) |
Oncolytics raised US$4.4M through the private sale of 2M units (6/10) |
|
|
|||
Ortec International Inc. (OTC BB: ORTN) |
Private placement of convertible preferred stock |
N/A |
$5.34 |
Ortec raised $5.34M in a private placement of convertible preferred stock at a fixed price of 20 cents each (6/2) |
|
||||
Orthovita |
Private placement of common stock and warrants |
4.9S and W for 0.979S |
$13.7 |
Orthovita raised about $13.7M after selling about 4.9M shares; investors also received five-year warrants to purchase about 979,000 common shares; SG Cowen Securities Corp. acted as the offering's placement agent (6/27) |
|
||||
OxiGene |
Private placement of common stock |
1.5S |
$15 |
OxiGene raised $15M with the sale of 1.5M shares to three institutional investors (6/10) |
|
||||
Peplin Biotech |
Private placement of common stock |
5S |
A$3.5 (US$2.3) |
Peplin Biotech raised US$2.3M with the placement of 5M shares to domestic and international institutional investors at 70 cents per share (6/2) |
|
||||
Peregrine Pharmaceuticals |
Private placement of common stock and warrants |
2.4S and 0.15W |
$2 |
Peregrine raised $2M through the sale of 2.4M shares and 150,000 warrants (6/10) |
|
||||
Peregrine Pharmaceuticals Inc. (PPHM) |
Private placement of common stock and the exercise of outstanding warrants |
1.6S and W for 3S |
$4 |
Peregrine raised $1.8M with the issuance of 1.6M shares to seven institutional investors; it also received $2.2M from the exercise of existing outstanding warrants issued in August 2002 for about 3M shares (6/27) |
|
||||
Pharming Group NV (the Netherlands; Pink Sheets: PHGUF) |
Private placement of common stock |
3.15S |
€4 (US$4.69) |
Pharming Group raised US$4.69M from European Bioscience Investments through the sale of 3.15M shares (6/4**) |
|
||||
Pharmos Corp. |
Private placement of common stock and warrants |
9.41S |
$8 |
Pharmos raised $8M, placing 9.41M shares and five-year warrants covering another 30% of the shares with 10 institutional investors; Rodman & Renshaw acted as lead placement agent (6/3) |
|
||||
Protein Polymer Technologies Inc. (OTC BB:PPTI) |
Private placement of preferred stock and warrants |
N/A |
$0.25 |
Protein Polymer raised $250,000 in a private placement of Series I convertible preferred stock and warrants; the company raised $3M in March in the first closing of the financing (6/10) |
|
||||
Proterion Corp. (AMEX:PRC) |
Credit facility |
N/A |
$1 |
Proterion raised $1M in a credit facility from KBK Financial Inc. (6/26) |
|
||||
Questcor Pharmaceuticals Inc. (AMEX:QSC) |
Private placement of common shares |
4.98S and W for 3S |
$5 |
Questcor raised $5M by issuing 4.98M shares; it also issued warrants for another 3M shares to the investors led by Broadwood Capital; other investors were Craig Drill Capital, Midsummer Capital, Islandia LP and others (6/17) |
|
||||
RegeneRx Biopharmaceuticals |
Private placement of common stock |
3.18S |
$2 |
RegeneRx raised $2M in proceeds from a private placement of stock with Defiante Farmaceutica Unipessoal LDA, a subsidiary of Sigma-Tau Finanziaria SpA (6/11) |
|
||||
Rigel Pharmaceuticals Inc. (RIGLD) |
Private placement of common stock and warrants |
72S and W for 14.4S |
$46 |
Rigel raised $46M after closing a private placement of common stock and warrants exercisable for additional shares of common stock; investors were MPM Capital, Frazier & Co., Alta Partners and HBM BioVentures AG (6/27) |
|
||||
SIGA Technologies |
Private placement of common stock and warrants |
1.25S and W for 0.625S |
$1.5 |
SIGA raised $1.5M from a private placement of 1.25M shares and warrants for 625,000 shares (6/24) |
|
||||
SuperGen Inc. |
Private placement of senior convertible notes |
N/A |
$21.25 |
SuperGen raised $21.25M in the financing; Rodman & Renshaw Inc. acted as placement agent (6/25) |
|
||||
Synthetic Blood International Inc. |
Private placement of common stock |
N/A |
$2 |
Synthetic Blood raised $2M in funds from a private investment source in Europe (6/24) |
|
|
|||
Targeted Genetics Corp. (TGEN) |
Private placement of common stock |
7.8S |
$17.55 |
Targeted Genetics raised $17.55M after placing 7.8M shares at $2.25 each; Roth Capital Partners LLC acted as placement agent for the financing, which included investments from Mainfield Enterprise Inc., Cranshire Capital LP, Smithfield Fiduciary LLC and Portside Growth & Opportunity Fund (6/18) |
|
||||
The Immune Response Corp. (IMNR) |
Private placement of promissory notes |
N/A |
$1 |
The Immune Response Corp. raised $1M in the private placement with accredited investors (6/26) |
|
||||
Tm Bioscience Corp. (Canada; VSE:TMC) |
Private placement of units |
23.2U |
C$5 (US$3.7) |
Tm Bioscience raised US$3.7M with the issuance of 23.2M units, each consisting of one common share and a half-share purchase warrant; Loewen, Ondaatje, McCutcheon Ltd. is lead placement agent, with support from Harris Partners Ltd. (6/16) |
|
||||
VaxGen Inc. |
Private placement of common stock |
1.6S |
$7 |
VaxGen raised $7M through the sale of about 1.6M shares of comon stock to a single institutional investor; Granite Financial Group Inc. acted as placement agent and Enable Capital LLC acted as adviser (6/9) |
|
||||
Vion |
Private placement of common stock |
3.8S |
$5 |
Vion raised $5M, issuing 3.8M shares to several institutional investors; Rodman & Renshaw acted as the transaction's placement agent, and Gerard Klauer Mattison acted as Vion's financial adviser (6/19) |
|
||||
|
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
